Pfizer, Inc. (PFE) Stock Analysis
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $25.33, but acceptable to hold if already in. Reasons: Thin upside margin: 3.7%; Weak growth.
Pfizer is a global biopharmaceutical company discovering, developing, and commercializing medicines and vaccines across oncology, internal medicine, vaccines, and inflammation/immunology. Revenue of ~$62B in 2025 spans 200+ countries; 12 products collectively represented 65% of... Read more
Hold if already holding. Not a fresh buy at $25.33, but acceptable to hold if already in. Reasons: Thin upside margin: 3.7%; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.4/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and news legal. Suitability: moderate.
Recent Developments — Pfizer, Inc.
Latest news
- Pfizer Stock Is Declining Today: What's Happening? - Benzinga — Benzinga negative
- Should You Buy, Sell, or Hold Pfizer at $27? - The Motley Fool — The Motley Fool positive
- Are Wall Street Analysts Bullish on Pfizer Stock? - Yahoo Finance — Yahoo Finance positive
- Pfizer (PFE) Stock Price Forecast: 2026, 2027, 2028–2030 and Beyond - LiteFinance — LiteFinance neutral
- 2 Trendlines in Focus For Pfizer Stock After Earnings - Schaeffer's Investment Research — Schaeffer's Investment Research neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductEliquis13%10-K Item 1A: 'Eliquis accounted for 13% of Total revenues in 2025.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $25.33, but acceptable to hold if already in. Reasons: Thin upside margin: 3.7%; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $26.27 (+3.7%), stop $24.43 (−3.7%), A.R:R 0.7:1. Score 5.4/10, moderate confidence.
Take-profit target: $26.27 (+3.7% upside). Target $26.27 (+3.7%), stop $24.43 (−3.7%), A.R:R 0.7:1. Stop-loss: $24.43.
Thin upside margin: 3.7%; Weak growth; Negative momentum.
Pfizer, Inc. trades at a P/E of 19.3 (forward 8.9). TrendMatrix value score: 7.3/10. Verdict: Hold.
36 analysts cover PFE with a consensus score of 3.5/5. Average price target: $29.
What does Pfizer, Inc. do?Pfizer is a global biopharmaceutical company discovering, developing, and commercializing medicines and vaccines across...
Pfizer is a global biopharmaceutical company discovering, developing, and commercializing medicines and vaccines across oncology, internal medicine, vaccines, and inflammation/immunology. Revenue of ~$62B in 2025 spans 200+ countries; 12 products collectively represented 65% of total revenues, with Eliquis alone at 13% of total revenues in 2025.